Niru Subramanian joined Orbital Therapeutics in January 2023 and brings 25 years of corporate strategy, operations and company building experience. Niru’s experiences include building new strategies and capabilities for high-growth organizations, leading multifunctional teams, managing partnerships and M&A transactions, and directing portfolio planning, alliance management, finance and operations. Prior to joining Orbital, she served as Chief Operating Officer of Rheos Medicines where she helped the company explore multiple strategic options including equity raise, mergers, acquisitions and asset sales. Prior to Rheos, she served as Senior VP, Corporate Development & Business Planning at Agios Pharmaceuticals, where she played an integral role in shaping the company’s strategy and led several key initiatives including the $2 billion sale of Agios’ oncology business in December 2020. Previously, Niru worked at Novartis Vaccines in a variety of roles, including as Vice President, Head of Influenza Global Programs, with responsibility for clinical development of pipeline assets, new product launch preparations, lifecycle management, and sales and profitability for the influenza vaccine franchise. Earlier in her career, she worked at The Boston Consulting Group in their healthcare practice area advising large and small biopharma companies on a variety of strategic and operational issues. Niru received a BS in Computer Science and Engineering from the University of Pennsylvania and an MBA from the Harvard Business School.